Prostacyclin eliminates the bioincompatibility of charcoal haemoperfusion.
During charcoal haemoperfusion (CHP) in dogs, use of prostacyclin (PGI2) in addition to heparin reduced the loss of platelets (25 +/- 6 vs 83 +/- 2%), the formation of platelet aggregates as judged by screen filtration pressure (65 +/- 6 vs 249 +/- 25mm Hg) and fibrinogen consumption (20 +/- 5 vs 46 +/- 6%). Prostacyclin also delayed neutralisation of heparin during CHP. This improvement of biocompatibility may now allow a proper assessment of CHP in liver failure.